(APOP), Quotes and News Summary

Cellect Biotechnology Ltd is a specialty pharmaceutical company for developing therapeutic products for the treatment of rare and orphan diseases. Its lead product, QRX003, is under development for the treatment of Netherton Syndrome, a rare hereditary skin disease. Its pipeline also includes potential treatments for other rare diseases including Peeling skin syndrome, SAM Syndrome, Palmoplantar Keratoderma, and Epidermolysis Bullosa.